Omega-3 Fish Oil: Benefits, Best Forms, Dosing, and Side Effects

1. Overview

Omega-3 fatty acids are a family of polyunsaturated fatty acids (PUFAs) characterized by a carbon-carbon double bond located three carbons from the methyl end of the fatty acid chain. The three omega-3s of greatest clinical importance are alpha-linolenic acid (ALA, 18 carbons), eicosapentaenoic acid (EPA, 20 carbons), and docosahexaenoic acid (DHA, 22 carbons) [1][2].

ALA and linoleic acid (an omega-6 fatty acid) are considered essential because the human body cannot synthesize them and they must be obtained from the diet. ALA can be converted to EPA and then to DHA in the liver, but conversion rates are very limited -- reported at less than 15% -- making direct consumption of EPA and DHA from fish, seafood, or supplements the only practical way to raise tissue levels [1][2]. However, non-fish eaters can maintain roughly similar levels of EPA, and only approximately 30% lower levels of DHA, compared to fish eaters based on red blood cell measurements (Harris, PLEFA 2025) [3].

EPA and DHA play critical structural roles as components of cell membrane phospholipids throughout the body [1][2]. DHA is especially concentrated in the retina, brain, and sperm [1][2]. Beyond their structural function, omega-3s serve as precursors to eicosanoids -- signaling molecules with wide-ranging effects on the cardiovascular, pulmonary, immune, and endocrine systems [1][2]. Eicosanoids derived from omega-3s are generally less pro-inflammatory than those derived from omega-6 fatty acids. Higher concentrations of EPA and DHA relative to arachidonic acid (an omega-6) shift the eicosanoid balance toward less inflammatory activity [1][2].

After ingestion, omega-3 fatty acids are hydrolyzed in the intestinal lumen. The hydrolysis products are incorporated into bile-salt-containing micelles and absorbed into enterocytes with an efficiency of approximately 95%, similar to other dietary fats [1]. Within intestinal cells, fatty acids are incorporated into chylomicrons and enter the circulation via the lymphatic system [1].

Table of Contents

• Overview
• Forms and Bioavailability
• Evidence for Benefits
• Recommended Dosing
• Safety and Side Effects
• Drug Interactions
• Dietary Sources
• References

The omega-3 index -- the content of EPA plus DHA in erythrocyte membranes expressed as a percentage of total erythrocyte fatty acids -- has been proposed as a biomarker for assessing omega-3 status [4][5]. An omega-3 index of approximately 8% or above is associated with lower risk of atherosclerotic cardiovascular disease, while an index below 4% is associated with the highest risk [4]. Approximately 89% of the US population is estimated to have an omega-3 index in the "high risk" category [6]. EPA and DHA typically comprise about 3-5% of erythrocyte fatty acids in Western populations with low fish intake, compared to approximately double that in Japan where fish consumption is high [1].

The IOM has established Adequate Intakes (AIs) for total omega-3s: 1.6 g/day for adult men and 1.1 g/day for adult women (as ALA). No specific intake recommendations for EPA and DHA have been established [1][2]. However, the American Heart Association recommends at least 1-2 servings (3.5 oz per serving) of non-fried, preferably fatty fish per week [7], and various expert bodies recommend 250-500 mg/day of combined EPA and DHA for general cardiovascular health [1][7][8].

2. Forms and Bioavailability

Chemical Forms

Omega-3 fatty acids in supplements exist in several distinct chemical forms, each with different absorption characteristics:

Natural Triglycerides: The form in which EPA and DHA naturally occur in fish oil -- fatty acids attached to a glycerol backbone. This is the least processed form. Typical concentration: about 30% EPA+DHA per gram of fish oil [3][9].

Ethyl Esters: Created by replacing the glycerol molecule with ethanol, allowing molecular distillation to purify and concentrate the oil. This is the most common form in supplements and prescription fish oils (Lovaza/Omacor) because it permits higher EPA+DHA concentrations (up to 84-96%). Most clinical studies have been conducted with this form [3][9].

Re-esterified Triglycerides: Made by converting ethyl esters back into triglycerides. This form has approximately 76% better absorption than ethyl esters and 34% better absorption than natural fish oil when taken without a high-fat meal (Dyerberg, PLEFA 2010) [9]. Some re-esterified triglyceride products contain a mix of triglycerides, diglycerides, and monoglycerides. A study comparing a >95% re-esterified triglyceride product (Ultimate Omega by Nordic Naturals) versus a <70% re-esterified product (MEG-3 by DSM) found slightly greater incorporation into red blood cell membranes with the higher-purity product after 4 months, though both were taken on an empty stomach (Minton, PLoS One 2023) [9].

Free Fatty Acids: The form found in prescription Epanova. The manufacturer claims better bioavailability than ethyl esters because free fatty acids do not require enzymatic breakdown before absorption and do not need to be taken with food. A study comparing Epanova and Lovaza found blood levels of EPA and DHA were 3 and 4 times higher, respectively, with Epanova when taken with a low-fat meal (Offman, Vasc Health Risk Manag 2013) [3].

Monoglycerides: A "pre-digested" form of fish oil. A study found that 6,000 mg of the monoglyceride form (MaxSimil) resulted in double the blood level of DHA+EPA compared to the same amount in ethyl ester form over 24 hours when given with a low-fat meal (Chevalier, Eur J Clin Nutr 2020). A subsequent study showed no difference in DHA absorption, though EPA absorption was 2-3 times higher with the monoglyceride form compared to triglyceride and ethyl ester forms (Chevalier, J Nutr 2021) [9]. The absorption of monoglyceride-form fish oil is similar to that of free fatty acids and similar to or slightly better than triglycerides when given to people on a low-fat diet (Cuenoud, Nutrients 2020) [9].

Phospholipids: The form found in krill oil. The phospholipid structure may enhance absorption. A 4-week study showed EPA from krill oil was absorbed 28% better than from fish oil, and DHA absorption was roughly comparable despite krill oil containing approximately half the DHA (Maki, Nutr Res 2009) [3][9].

Key Absorption Principles

Taking fish oil with a fatty meal dramatically improves absorption. Fats trigger bile release into the small intestine, causing emulsification that facilitates absorption (Dyerberg, PLEFA 2010). When fish oil is taken with a high-fat meal, studies show little or no difference in absorption among the various forms (Nordoy, Am J Clin Nutr 1991; Lawson, Biochem Biophys Res Commun 1988) [9].

Self-emulsifying formulations may improve fasted absorption. A self-emulsifying fish oil showed 8.2-fold higher bioavailability for EPA+DHA than non-emulsified Lovaza when taken without food, particularly for EPA (18.3-fold higher) (Maki, Clin Therapeutics 2018) [9].

Form summary: After digestion, all forms end up as the same free fatty acids in the blood. If taken with a fatty meal, all forms are equally well absorbed over 24 hours. If taken without food, the re-esterified triglyceride, natural triglyceride, and monoglyceride forms have meaningfully better absorption than ethyl esters [9].

Supplement Sources

Source	EPA:DHA Ratio	Key Features
Fish oil (standard)	~1.5:1 (e.g., 180 mg EPA / 120 mg DHA per 1 g)	Most studied, most widely available, lowest cost [3][9]
Fish oil (concentrated)	Variable, up to 96% EPA+DHA	Fewer capsules needed. Prescription versions: Lovaza (84% EPA+DHA), Vascepa (96% EPA only) [3]
Krill oil	~2:1 EPA:DHA	Contains phospholipids and astaxanthin. Possibly better absorption of EPA. More expensive [3][9]
Algal oil	Higher DHA than EPA	Vegetarian/vegan option. DHA in triglyceride form. Very low contaminants. High-dose algal DHA lowers triglycerides by ~15% and raises HDL by ~5% (Bernstein, J Nutr 2012) [3][9]
Calamari (squid) oil	Higher DHA than EPA	Short-lived species, lower toxin accumulation. Sourced from food production by-products [9]
Cod liver oil	Variable	Contains vitamins A and D. Risk of excessive vitamin A if combined with other supplements [3][9]

DPA: The "Other" Omega-3

Docosapentaenoic acid (DPA) is the third most prevalent omega-3 in fish oil, typically comprising 2-5% of total omega-3 fatty acids. Higher blood levels of DPA have been associated with lower blood triglycerides, lower cholesterol and inflammation, and lower risk of heart attack and coronary heart disease [9]. A 13-year study of over 2,500 older adults found that having the highest blood levels of EPA and DPA (but not DHA) was associated with a 24% and 18% lower risk of unhealthy aging, respectively (Lai, BMJ 2018) [9]. DPA may act as a "reservoir" for EPA and DHA that the body converts as needed (Miller, Eur J Nutr 2013) [9].

Rich food sources of DPA include raw salmon (393 mg per 3.5 oz), Atlantic mackerel (200 mg), and Pacific herring, bluefin tuna, and rainbow trout (100-200 mg each) [9].

3. Evidence for Health Benefits

Cardiovascular Disease and Stroke

Overall Evidence

Eating non-fried fish or taking high-dose prescription fish oil containing EPA and DHA has several potentially heart-healthy effects: reducing triglyceride levels, slightly raising HDL cholesterol, possibly "thinning" the blood, reducing homocysteine levels, and lowering blood pressure [3][7]. However, fish oil supplements have shown inconsistent and inconclusive evidence of cardiovascular benefit, particularly among people without risk factors for heart disease [3][10].

Increased consumption of fish oils from food and higher blood levels of omega-3s have been associated with reduced cardiovascular disease risk and mortality, with researchers indicating that the high blood levels could be achieved with an average daily intake providing 250-400 mg of EPA+DHA from a moderate amount of fish (Mozaffarian, Ann Int Med 2013) [3].

Key Clinical Trials

VITAL study (n=25,871, 5 years): Among a cross-section of older Americans, supplementing with fish oil (460 mg EPA + 380 mg DHA daily) did not reduce the incidence of major cardiovascular events overall. However, among people consuming less than 1.5 servings of fish per week, fish oil supplementation resulted in a 19% reduction in major cardiovascular events and a 40% reduction in heart attacks. African Americans experienced a 77% reduction in heart attacks compared to placebo. There was a significant 28% reduction in total myocardial infarction rates and significant reductions in fatal MI, total coronary heart disease, and percutaneous coronary intervention (Manson, NEJM 2018) [3][10].

ASCEND study (n=15,480, 7.4 years): Among adults with type 1 or type 2 diabetes, 1 g/day of fish oil (460 mg EPA + 380 mg DHA) showed no statistically significant cardiovascular benefit compared to olive oil placebo. However, omega-3 supplementation did significantly reduce the risk of cardiovascular death by 19% (ASCEND Study, NEJM 2018) [3][10].

REDUCE-IT (n=8,179, 4.9 years): High-dose icosapent ethyl (Vascepa, 4 g/day providing 3,840 mg EPA) among statin-treated patients with elevated triglycerides and cardiovascular risk factors demonstrated a 25% reduction in first cardiovascular events (cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, unstable angina). A second analysis counting all events showed a 30% reduction. Vascepa also significantly reduced cardiovascular death by 20%, fatal or nonfatal stroke by 28%, and fatal or nonfatal myocardial infarction by 31% (Bhatt, NEJM 2018; Bhatt, J Am Coll Cardiol 2019) [3][10].

REDUCE-IT plaque substudy (n=80, 18 months): Vascepa reduced total coronary plaque by 9% versus an 11% increase with placebo. Low-attenuation plaque (a strong predictor of heart attack) decreased by 17% versus a 109% increase with placebo (Budoff, Eur Heart J 2020) [3].

STRENGTH (n=13,078, ~3.5 years): High-dose Epanova (4 g/day EPA+DHA in carboxylic acid form) did not reduce cardiovascular events compared to corn oil placebo. The trial was stopped early due to low likelihood of benefit. Epanova reduced triglycerides by 19% but increased atrial fibrillation risk (2.2% vs 1.3% with placebo) (Nicholls, JAMA 2020) [3][10]. A post-hoc analysis found that participants in Asian countries did benefit -- Epanova reduced major adverse cardiovascular events by 28% among Asian participants (Wang, Atherosclerosis 2025) [3].

Mineral oil placebo controversy: The conflicting results between REDUCE-IT and STRENGTH may partially be explained by the mineral oil placebo used in REDUCE-IT. Mineral oil is not a neutral placebo -- it affects lipid levels, inflammatory markers, and may inhibit statin absorption. Researchers estimated that approximately half of the estimated benefit found with Vascepa versus Epanova might be due to negative effects of mineral oil (Doi, Eur Heart J 2021; Nissen, JAMA Cardiol 2021) [3][10].

End-stage kidney disease (n=1,228, 3.5 years): Fish oil (4 g/day providing 1,600 mg EPA + 800 mg DHA in ethyl ester form) reduced serious cardiovascular events by 43% in adults on hemodialysis compared to corn oil placebo (Lok, N Engl J Med 2025) [3].

UK Biobank observational study (n=427,678, 8-9 years): Fish oil supplement users had a 13% lower risk of all-cause mortality, 16% lower risk of cardiovascular death, and 7% lower risk of any cardiovascular event compared to non-users (Li, BMJ 2020) [3].

Japan EPA Lipid Intervention Study (n=18,645, 4.6 years): Among people with hypercholesterolemia, 1.8 g/day EPA plus a statin reduced major coronary events by 19% versus statin alone. Benefits were concentrated in those with existing coronary artery disease (28% reduction in unstable angina, 19% reduction in major coronary events) [10].

Meta-analysis (127,477 participants, 13 trials): A 2019 systematic review concluded that long-chain omega-3 supplementation reduces the risk of myocardial infarction, coronary heart disease death, total coronary heart disease, CVD death, and total CVD in a dose-related manner, but does not significantly reduce stroke risk. The authors noted that the 4 g/day dose in REDUCE-IT was needed to affect stroke outcomes (Hu, J Am Heart Assoc 2019) [10].

Cochrane Review (162,796 participants, 86 RCTs): A 2020 review found 0.5-5+ g/day long-chain omega-3s reduced serum triglycerides by about 15% and slightly decreased cardiovascular mortality and coronary heart disease events, but did not affect all-cause mortality, cardiovascular events, stroke, or arrhythmia (Abdelhamid, Cochrane Database Syst Rev 2018/2020) [10].

Heart Failure

Fish oil supplementation may benefit people with chronic heart failure. In 31 patients with chronic heart failure, 2,000 mg of concentrated fish oil (920 mg DHA + 760 mg EPA) daily for two months improved left ventricle ejection fraction by 3%, increased flow-mediated dilation by 33%, and reduced markers of cardiac inflammation and fibrosis compared to placebo. The greatest improvements were in those with lower baseline NT-proBNP levels (Oikonomou, Clin Nutr 2019) [3].

Analysis of VITAL data showed fish oil reduced first heart failure hospitalization by 31% and recurrent heart failure hospitalization by 47% among those with type 2 diabetes, but showed no benefit in those without diabetes. There was also a 35% reduction in recurrent heart failure hospitalization among Black participants (Djoussé, JAAC Heart Fail 2022). An earlier Italian study of older people (~60% with type 2 diabetes) similarly found 1 g fish oil daily for 5 years reduced heart failure hospitalization by 33% (Roncaglioni, N Engl J Med 2013) [3].

However, a 1-year study of 56 obese adults at high risk of heart failure found 1.6 g/day fish oil did not reduce myocardial triglyceride content, visceral fat, or improve heart structure/function compared to placebo. Adding fish oil to high-intensity interval training did not improve outcomes beyond HIIT alone (Hearon, JAAC: Heart Failure 2022) [3].

Post-Heart Attack Recovery

Among 360 men and women who began taking high-dose Lovaza (1,500 mg DHA + 1,860 mg EPA) within one month of a heart attack, the heart's pumping ability modestly improved after 6 months compared to placebo, with no reports of bleeding. Follow-up at 6.6 years showed that, overall, those who received Lovaza did not have a lower risk of recurrent events, but the subgroup of individuals who achieved at least a 5% increase in omega-3 index had a 41% lower rate of major adverse cardiovascular events. Genetic profiles (FADS2 gene) that promote greater omega-3 index response may predict who benefits most (Heydari, Circulation 2016; Bernhard, Int J Cardiol 2024) [3].

Statins and Fish Oil

Adding high-dose fish oil to statin therapy helps lower triglycerides but has mixed effects on total cholesterol and generally does not slow coronary plaque progression, with one notable exception.

In men and women with high triglycerides despite statin therapy, adding 1,520 mg DHA + 1,840 mg EPA daily decreased triglycerides by 26% versus 2% with placebo (Kim, Clin Ther 2018). Similar results were found with atorvastatin (Jun, Diabetes Metab J 2019) [3].

Among adults on atorvastatin with elevated lipoproteins, 4,000 mg/day omega-3 (750 mg EPA + 250 mg DHA ethyl esters) for 8 weeks reduced triglycerides by 21.5%, VLDL by 36.9%, and small dense LDL (the most atherogenic subclass) by 67.5% compared to placebo. There was no significant change in overall LDL or HDL cholesterol (Us, Lipids Health Dis 2022) [3].

In patients with familial hypercholesterolemia on statin therapy, 1,840 mg EPA + 1,520 mg DHA daily for 3 months lowered total cholesterol by 9.28 mg/dL, LDL by 7.73 mg/dL, and triglycerides by 12.4 mg/dL more than placebo, and increased large HDL (inversely associated with CVD). However, it did not lower apolipoprotein B (Hande, Biomedicines 2022) [3].

An important finding: High-dose fish oil (1,860 mg EPA + 1,500 mg DHA from Lovaza) prevented fibrous coronary plaque progression in people on low-dose statins over 30 months. Fibrous plaque increased 5% in non-fish-oil users versus no increase with fish oil. Among low-dose statin users, those receiving fish oil also had significantly lower musculoskeletal events, infections, and joint replacement rates (Alfaddagh, J Am Heart Ass 2017) [3].

However, among patients with coronary artery disease on high-dose statin therapy whose LDL and triglycerides were already well-controlled, adding 2 g of omega-3 fatty acids once or twice daily did not further reduce coronary plaques, LDL, or triglycerides (Nakao, J Atheroscler Thromb 2023). A 3-year Japanese post-marketing study of the same prescription fish oil among 14,364 people also showed no decrease in cardiovascular events versus statin alone (Teramoto, Expert Opin Drug Saf 2022) [3].

Summary of Cardiovascular Evidence

• There is no reliable evidence that fish oil supplements prevent heart disease in healthy people without risk factors [3][10]
• Fish oil supplementation may help people who do not regularly eat fish, those with chronic heart failure and reduced ejection fraction, and those who have recently had a heart attack [3]
• High-dose fish oil (>3 g/day EPA+DHA) effectively lowers triglycerides in people with severe hypertriglyceridemia [3][7][10]
• Fish oil supplementation along with 3+ servings of fish per week may reduce venous thromboembolism risk [3]
• Any cardiovascular benefit of supplementation may be limited to people who do not regularly consume fish and are not taking other heart medications [3]

Triglyceride Reduction

The American Heart Association has concluded that prescription omega-3s (EPA+DHA or EPA-only) at 4 g/day (providing >3 g/day total EPA+DHA) are an effective and safe option for reducing triglycerides, as monotherapy or as an adjunct to other lipid-lowering agents (Skulas-Ray, Circulation 2019) [7].

Prescription Lovaza (840 mg EPA+DHA per capsule, 4 g/day) has been shown to lower triglycerides by 20-30% in clinical studies (Koski, PT 2008) [3].

Prescription Epanova (free fatty acid form) lowered triglycerides by 30% at the 4 g/day dose and 26% at the 2 g/day dose (Kastelein, J Clin Lipidol 2014) [3].

Prescription Vascepa (96% EPA ethyl ester, 4 g/day) decreased triglycerides by 21-33% over three months without significantly raising LDL cholesterol (Nelson, Ann Pharmacother 2013) [3].

A meta-analysis found a dose-response relationship: each increase of 1 g/day of long-chain omega-3 intake reduced triglycerides by 5.9 mg/dL, with stronger effects in people with higher baseline triglyceride levels [10].

Depression and Anxiety

Depression Treatment in Adults

Fish oil providing more EPA than DHA (typically at least 60% EPA of total omega-3s) at doses of 1,000-4,000+ mg/day has the strongest evidence for treating existing depression, particularly as an adjunct to antidepressant medication [3].

Treatment of depression using high-dose omega-3s with more than 50% EPA was shown to have the strongest evidence of benefit of any supplement type used for treating mental disorders, according to an analysis of 33 meta-analyses. The evidence was particularly strong for use in conjunction with SSRI medication (Firth, World Psych 2019) [3].

In depressed older women in a nursing home, 2,500 mg/day omega-3 (1,670 mg EPA + 830 mg DHA) for 8 weeks resulted in depression remission in 40.9% versus 16.7% with placebo. Further blood analysis showed elderly depression is characterized by very low EPA levels in red blood cell membranes, and EPA-rich supplementation restored concentrations to normal (Rondanelli, J Am Col Nutr 2010; Rizzo, Nutr J 2012) [3].

The combination of EPA plus fluoxetine was superior to either alone for major depression in an 8-week study of 60 people [3].

Among overweight adults with untreated major depression, approximately 4 g EPA + 1 g DHA daily for 12 weeks produced a 64% response rate versus 40% for placebo. Lower doses (half and quarter) were not significantly better than placebo (Mischoulon, J Clin Psychiatry 2022) [3].

In young adults (average age 20) with mild to moderate depression, 1,000 mg EPA + 400 mg DHA daily for 21 days resulted in 67% no longer being clinically depressed versus 20% in the placebo group (Ginty, Psychiatry Res 2015) [3].

An earlier study found that only 1,000 mg/day of EPA had a significantly better outcome than placebo, while 2,000 mg and 4,000 mg doses did not (Peet, Arch Gen Psychiatry 2002), suggesting a possible U-shaped dose-response for EPA alone [3].

A possible mechanism: Fish oil increases white matter (myelinated fibers connecting brain cells) in brain areas compromised in depression. Among 16 acutely depressed adults, 80% of those whose depression improved on 4 g/day fish oil (1,600 mg EPA + 800 mg DHA) showed white matter increases in key brain regions (Chhetry, J Psychiatr Res 2016) [3].

The International Society for Nutritional Psychiatry Research (2019) recommends 1-2 g/day of either pure EPA or a combination with EPA:DHA ratio >2:1 for at least 8 weeks as adjunctive therapy for major depressive disorder (Guu, Psychother Psychosom 2019) [3].

Fish oil with more DHA than EPA has generally not been helpful for depression in adults already on medication (Piperoglou, J Clin Psychopharmacol 2023) [3].

Krill oil (340 mg EPA + 180 mg DHA/day) and fish oil (340 mg EPA + 240 mg DHA/day) for 8 weeks produced slight decreases in depression and anxiety in adults with mild to moderate major depression, but the improvements were below the threshold for clinical meaningfulness (Acik, J Affect Disord 2025) [3].

Depression Prevention

Evidence is mixed. Among older adults without depression, 1 g/day fish oil for ~5.3 years did not prevent depression and slightly increased its incidence by about 13% (Okereke, JAMA 2021). However, among older adults with a history of major depression in China, 1.2 g EPA + 1 g DHA daily for 52 weeks significantly reduced relapses -- 53% relapsed versus 85% in the placebo group (Cheng, J Affect Disord 2024) [3].

Depression in Children and Adolescents

Most clinical studies suggest fish oil does not improve depression in children, teens, or young adults, though results conflict [3]. A study in 257 children and adolescents with major depression showed no benefit from EPA+DHA over 36 weeks compared to placebo, even when controlling for antidepressant use, despite omega-3 index increasing from 4.68% to 9.56% (Berger, JAMA Netw Open 2026) [3].

A 10-week study of adolescents with moderate to severe depression found both fish oil and placebo (soybean/corn oil) equally reduced depression severity (Gabbay, J Clin Psychiatry 2018). Similarly, 840 mg EPA + 560 mg DHA daily for 3 months did not improve depression in 181 young adults with major depression (Amminger, Biol Psychiatry 2023) [3].

However, a study in Slovakia found 1,000 mg EPA + 750 mg DHA for 3 months reduced depression severity by 25% versus 9% with placebo in youth taking SSRIs, though the fish oil was not effective in those with mixed depression and anxiety (Trebaticka, Child Adolesc Psych Ment Hlth 2017) [3].

Anxiety

Fish oil supplementation was associated with a modest improvement in anxiety among people with clinically diagnosed conditions, according to an analysis of 19 controlled trials. The effect was greater at doses of 2,000+ mg/day EPA+DHA and when the EPA/DHA ratio was less than 60%. Among US medical students, 2,496 mg omega-3 daily (2,085 mg EPA + 348 mg DHA) for 12 weeks reduced anxiety symptoms by 20% and decreased the inflammatory marker IL-6 by 14% (Kiecolt-Glaser, Brain Behav Immun 2011; Su, JAMA Network Open 2018) [3].

A study among 64 adults with high mental distress showed 1,000 mg fish oil daily (500 mg EPA + 250 mg DHA) for 3 months significantly reduced perceived stress by 16.12 points, depression by 9.13 points, and anxiety by 8.13 points, and improved memory and sleep quality compared to placebo (Azhar, J Affect Disord 2026) [3].

Stress

High-dose fish oil (9 g daily providing 1,600 mg EPA + 1,100 mg DHA) for 8 weeks slightly blunted heart rate and nervous system responses to mental stress in young adults (Carter, Am J Physiol 2013). However, another study found 4 g/day fish oil (2,200 mg EPA + 440 mg DHA) for 3 months did not reduce psychological stress in adults with chronic moderate-to-high work stress (Bradbury, Front Pharmacol 2017) [3].

Cognitive Function and Alzheimer's Disease

Age-Related Cognitive Decline

Observational research among older individuals has found associations between fish oil supplement use and less cognitive decline and brain volume loss, but primarily in those with normal cognitive function who do not carry the APOE e4 gene (Daiello, Alzheimer's & Dementia 2015; Keenan, Alz Dem 2020) [3].

Among several hundred people with age-related cognitive decline, 900 mg/day DHA from algal triglycerides for 24 weeks significantly improved verbal recognition memory (though not working memory or executive function). Plasma DHA levels doubled (Yurko-Mauro, Alzheimer's & Dementia 2010) [3].

In 250 cognitively healthy people with coronary artery disease, high-dose Lovaza (1,860 mg EPA + 1,500 mg DHA) for 30 months improved verbal fluency, language, memory, and visual-motor coordination compared to controls. Improvements were observed starting at 12 months and persisted through 30 months (Malik, Am J Clin Nutr 2021) [3].

In 65 healthy adults ages 50-75, fish oil (1,200 mg EPA + 880 mg DHA) for 6 months produced a 26% improvement in executive functioning, improvements in memory consolidation, structural brain gains, and a 3.4% reduction in diastolic blood pressure (Witte, Cereb Cortex 2013) [3].

In healthy young adults with diets low in omega-3s, DHA-rich fish oil (1,160 mg DHA + 170 mg EPA) for 6 months improved memory: women improved episodic memory (correctly remembering one more word or picture), while men had 20% faster working memory reaction times (Stonehouse, Am J Clin Nutr 2013) [3].

However, multiple studies in well-nourished populations with regular fish intake have found no cognitive benefit (Chew, JAMA 2015; Andrieu, Lancet Neurol 2017; Danthiir, Am J Clin Nutr 2018). Benefits tend to be limited to people with low baseline DHA levels or low fish intake [3].

Among 271 healthy adults with low omega-3 intake, 1,000 mg EPA + 400 mg DHA daily for 4 months did not improve cognition -- only those with the lowest baseline DHA levels showed improvement in executive functioning (Leckie, Psychol Med 2019). A 6-month study of 193 healthy adults found improvement only in those with low baseline episodic memory scores (Maltais, Prostaglandins Leukot Essent Fatty Acids 2022) [3].

Mild Cognitive Impairment

DHA-rich fish oil may help reduce further cognitive decline in people with MCI, particularly those with lower baseline omega-3 levels. A study of healthy older individuals in China with MCI found 2 g/day algal DHA for 1 year improved short- and long-term memory and increased hippocampal volume by 4% (Zhang, J Alz Disease 2016). Another study found 480 mg DHA + 720 mg EPA daily improved cognitive function, perceptual speed, and working memory in older adults with MCI who had somewhat low baseline EPA+DHA levels (Bo, Nutrients 2017) [3].

High-DHA supplementation (1,550 mg DHA + 400 mg EPA) for 6 months improved verbal fluency and reduced depressive symptoms in MCI patients, while EPA-dominant supplementation (1,670 mg EPA + 160 mg DHA) reduced depression but did not affect cognition (Sinn, Br J Nutr 2011). The researchers noted that depression is a potential risk factor for progression to dementia [3].

However, studies in New Zealand (1,491 mg DHA + 351 mg EPA for 1 year) and the UK/Australia (1,100 mg DHA + 400 mg EPA for 1 year with chocolate) showed no cognitive benefits in MCI patients, possibly because participants had higher IQ scores and greater cognitive reserve (Mengelberg, Int J Geriatr Psychiatry 2022; Vauzour, Am J Clin Nutr 2023) [3].

Alzheimer's Disease

Fish oil alone has not shown benefit in treating or slowing Alzheimer's disease. In patients given 2 g/day DHA from algal oil for 18 months, there was no reduction in cognitive decline despite tripling plasma DHA and increasing cerebrospinal fluid DHA by 38% (Quinn, JAMA 2010). Additional analysis suggested some reduction in aggressive behavior, though not statistically significant (Perales-Puchalt, Alzheimer Dis Assoc Disord 2025) [3].

However, omega-3s may benefit Alzheimer's patients when combined with adequate B vitamins. In patients with mild to moderate Alzheimer's, daily supplementation with 1,700 mg DHA + 600 mg EPA for 6 months benefited only those with adequate B vitamin status (homocysteine <11.7 mmol/L) -- these patients showed a 7.1% improvement in cognitive performance and 22.3% reduction on a dementia rating scale. The explanation: B vitamins are necessary to form phosphatidylcholine, which carries DHA and EPA across the blood-brain barrier (Jerneren, J Alz Dis 2019) [3].

Similarly, a pilot study found that alpha-lipoic acid (600 mg) plus fish oil (975 mg EPA + 675 mg DHA) slowed cognitive and functional decline over 1 year in mild-to-moderate Alzheimer's patients (Shinto, J Alzheimers Dis 2014) [3].

A 3-year study in 102 older adults without dementia but with low omega-3 levels found fish oil (975 mg EPA + 650 mg DHA) did not significantly reduce cerebral white matter lesions or brain atrophy overall, but did significantly reduce nerve cell breakdown among APOE e4 carriers (Shinto, JAMA Netw Open 2024) [3].

Rheumatoid Arthritis and Inflammatory Conditions

Rheumatoid Arthritis

Consistent long-term intake of >210 mg/day omega-3s from fish was associated with a 52% lower risk of developing rheumatoid arthritis over 7.5 years in Swedish women (Di Giuseppe, Ann Rheum Dis 2013). The VITAL trial found 1 g/day concentrated fish oil reduced the overall risk of autoimmune disease by 15%, with apparent reductions of 42% for rheumatoid arthritis, 47% for thyroid disease, and 57% increased risk of psoriasis. People with lower BMI and family history of autoimmune disease benefited most (Hahn, BMJ 2022) [3].

An analysis of 22 clinical studies concluded that marine oils reduce pain (but not joint function) associated with rheumatoid arthritis, with best results using products with at least 50% more EPA than DHA (Senftleber, Nutrients 2017) [3].

Fish oil has also been associated with increased blood levels of specialized pro-resolving mediators (SPMs) -- protectins and resolvins that act to inhibit the inflammatory response -- in people both with and without rheumatoid arthritis (Marchhand, Prostaglandins Leukot Essent Fat Acids 2023) [3].

A study of 38 patients with RA found 2,100 mg/day DHA from microalgae oil for 10 weeks significantly decreased the number of tender and swollen joints from about 14 to 10, while the placebo group worsened from about 10 to 12 (Dawczynskia, Clin Nutr 2017) [3].

Osteoarthritis

Most studies have not found fish oil to reduce osteoarthritis pain (Senftleber, Nutrients 2017). However, in older, obese adults with mild chronic osteoarthritis who did not consume much fish, 1,000 mg DHA + 200 mg EPA taken twice daily reduced average overall pain by 42% compared to no treatment. Interestingly, adding curcumin provided less pain relief than fish oil alone (Kuszewski, Rheumatol Adv Pract 2020) [3].

High-dose Lovaza (1,860 mg EPA + 1,500 mg DHA) for 1 year in coronary artery disease patients prevented worsening of arthritic pain, stiffness, and function, while the control group deteriorated. The fish oil group reported more exercise (197 vs 135 minutes/week) and less joint replacement surgery (0% vs 3.1%) (Alfaddagh, J Clin Lipidol 2018) [3].

Krill oil has shown limited benefit for osteoarthritis. A study of 222 people found no benefit from 2 g/day krill oil for 6 months, and those in the placebo group actually showed reduced joint swelling (Laslett, JAMA 2024). A higher dose (4 g/day) showed a modest 5.2-point greater pain reduction versus placebo at 6 months, which was clinically insignificant (Stonehouse, Am J Clin Nutr 2022) [3].

Gout

Eating fish low in purines may help, but there is no evidence that fish oil supplements are helpful. Consuming fish rich in omega-3s was associated with a protective effect against recurrent gout attacks, but taking fish oil supplements was not (Zhang, American College of Rheumatology Annual Meeting 2015). Fish oil supplements contain minimal purines (Roy, Food Nutr Sci 2013). People with gout should limit sardines, mackerel, and herring due to high purine content in the meat, but purines are largely eliminated in fish oil manufacturing [3].

Ulcerative Colitis and Crohn's Disease

People consuming the highest amounts of DHA (410-2,000 mg/day) had a 77% lower risk of developing ulcerative colitis over 4 years (Hart 2009). In patients with stable ulcerative colitis, 1,000 mg EPA twice daily for 6 months maintained remission in 76.7% versus 50% of placebo recipients, and reduced fecal calprotectin (a marker of mucosal inflammation) in 63.3% versus 13.3% (Scaioli, Clin Gastro Hep 2018). However, in Crohn's disease, 4 g/day omega-3 (50-60% EPA + 15-25% DHA) was ineffective at preventing relapse [3].

Cancer

Prevention

A 3-year study of 2,157 healthy people aged 70+ in five European countries found 1 g/day algal oil (167 mg EPA + 333 mg DHA) reduced invasive cancer risk by 30%, and by 48% when combined with regular strength training. Combined with vitamin D, the risk decreased by 47%, and with both vitamin D and strength training by 61%. Overall cancer incidence was 3.8% (81 total cases) (Bischoff-Ferrari, Front Nutr 2022) [3].

The VITAL study found fish oil + vitamin D did not reduce overall cancer risk, but a subgroup analysis showed supplementation reduced precancerous colorectal growths by 41% in African Americans and by 24% in those with low baseline omega-3 levels (Song, JAMA Oncol 2019). People diagnosed with colorectal cancer who consume at least 300 mg/day omega-3 from fish/supplements have a 41% lower risk of dying from the disease (Song, Gut 2016). However, high-dose Lovaza for 6 months did not affect colorectal cell replication or cell death (Murff, Nutr Cancer 2021) [3].

For breast cancer, current use of fish oil supplements was associated with a 32% reduction in risk among postmenopausal women, with the greatest reduction in ductal carcinoma (Brasky, Canc Epidemiol Biomarkers Prev 2010). Women with early-stage breast cancer consuming >73 mg/day DHA+EPA from fish had a 25% lower recurrence risk (Patterson, J Nutr 2011). Higher tuna and baked/broiled fish consumption was associated with a 25-34% reduced risk of death from all causes in women with breast cancer over 15 years (Khankari, Cancer 2015) [3].

Evidence for prostate cancer is mixed and concerning. A 6-year study found no association between fish oil use and prostate cancer development (Brasky, Nutr Cancer 2011). However, men with the highest blood levels of DHA+EPA and DPA were 44% and 71% more likely to develop low-grade and high-grade prostate cancers, respectively (Brasky, JNCI 2013). A study of 100 men on active surveillance for prostate cancer found fish oil (2.2 g/day) with a low-fat diet had no impact on cancer grade or PSA levels, though there was a 31% greater decline in the Ki-67 index (tumor cell division rate) (Aronson, J Clin Oncol 2024) [3].

During Chemotherapy

Fish oil may prevent weight loss during chemotherapy. Patients with non-small cell lung cancer given 2.2 g/day EPA during chemotherapy maintained weight while non-supplemented patients lost an average of 5 lbs (Murphy, Cancer 2011). However, 16:4(n-3) fatty acid in fish oil may activate white blood cells leading to chemoresistance in mice -- patients are advised to avoid fish oil from the day before through the day after chemotherapy, as well as herring and mackerel in the 48 hours surrounding treatment (Daenen, JAMA Oncology 2015) [3].

Pregnancy and Infant Development

Preterm Birth

DHA supplementation during pregnancy may reduce the risk of premature birth, especially among women with low omega-3 levels. A Cochrane Review of 70 RCTs (n=19,927) concluded that long-chain omega-3s reduced the risk of preterm birth (<37 weeks) by 11% and early preterm birth (<34 weeks) by 42%, and reduced the risk of low birthweight (Middleton, Cochrane Database Syst Rev 2018) [1][10].

In an Australian study, maternal fish oil (800 mg DHA + 100 mg EPA) significantly decreased very premature births (1.09% vs 2.25%) and low-birth-weight infants (Makrides, JAMA 2010) [3].

In a US study, women with low baseline DHA levels who took 1,000 mg/day DHA from algal oil had half the rate of early preterm birth compared to those on 200 mg/day (2% vs 4.1%). Women with already-high DHA levels had the lowest rate (1.2%) regardless of dose, suggesting supplementation may not provide additional benefit when levels are adequate (Carlson, EClinicalMedicine 2021) [3].

However, DHA supplementation later in pregnancy (24-34 weeks) does not appear to benefit women with threatened preterm labor (Phattharachindanuwong, Int J Women Health 2025) [3].

European experts recommend all pregnant women obtain at least 250 mg/day DHA+EPA and an additional 100-200 mg/day DHA, with women at risk for preterm birth due to low DHA intake receiving 600-1,000 mg/day, starting by 20 weeks gestation and continuing until 37 weeks (Cetin, Am J Obstet Gynecol MFM 2024; Savona-Ventura, Eur J Obstet Gynecol Reprod Biol 2024) [3].

Allergy and Asthma in Offspring

A major Danish study found maternal fish oil supplementation (1,320 mg EPA + 880 mg DHA daily from 24 weeks gestation) decreased persistent wheeze and asthma in offspring by age 5 -- 16.9% versus 23.7% with placebo. In women with lower baseline omega-3 levels, the benefit was even greater (17.5% vs 35.1%). US women tend to consume half the omega-3 from diets as Danish women, suggesting potentially greater benefit in the US (Bisgaard, NEJM 2016) [3].

Follow-up at age 10 found fish oil reduced atopic dermatitis risk by 30% in children whose mothers had the most common COX1 TT gene (61% of mothers). However, children of mothers with the least common COX1 CC gene (6% of mothers) had a 500% increased risk (Chen, JAMA Dermatol 2024) [3].

Infants of fish-oil-supplemented mothers were ~40% less likely to have egg allergies in their first year (Palmer, BMJ 2012) [3].

Respiratory Infection in Infants

In Mexico, infants born to women given 400 mg DHA daily during pregnancy had slightly lower cold occurrence in the first 3 months (37.6% vs 44.6%) (Imhoff-Kunsch, Pediatrics 2011). A Norwegian study found each 1 g/day increase in maternal omega-3 intake was associated with a 1% lower risk of upper respiratory tract infection in children during the first 3 years (Rantala, J Nutr 2026) [3].

Cognitive Effects

Fish oil supplementation during pregnancy does not appear to significantly benefit offspring cognition. An Australian study found no significant improvement in cognitive or language development through ages 4 and 7, and children had slightly more behavioral and executive functioning problems at age 7 (Makrides, JAMA 2010, 2014; Gould, JAMA 2017). A Spanish study also found no improvement in memory, attention, motor skills, or language at age 9 (Azaryah, Nutrients 2020) [3].

However, higher-dose DHA (800 mg vs 200 mg) during pregnancy was associated with 10-15 seconds faster visual learning in infants at 6 months (Colombo, Dev Psychobiol 2025) [3].

Fertility

In overweight/obese women with PCOS-related infertility, 3,000 mg fish oil daily (1,080 mg EPA + 720 mg DHA) during ovulation stimulation significantly increased pregnancy rates among overweight/obese participants (29.6% vs 5.3% with placebo) (Trop-Steinberg, Isr Med Assoc J 2023) [3].

Dry Eye

The majority of evidence from clinical studies has not found that omega-3 supplementation alone significantly helps treat or prevent dry eye [3].

The largest study (University of Pennsylvania/National Eye Institute) gave fish oil (2,000 mg EPA + 1,000 mg DHA) or olive oil to hundreds of patients with moderate to severe dry eye for 12 months. Both groups improved similarly, with the disease severity score improving by about 13 points out of 100 (Asbell, N Engl J Med 2018) [3].

A 5-year study from VITAL (n=23,523) showed 460 mg EPA + 380 mg DHA daily did not reduce dry eye incidence, even among those with low fish intake or low baseline omega-3 levels (Christen, JAMA Ophthalmol 2022) [3].

There are exceptions: Fish oil helped dry eye associated with contact lens use -- 900 mg EPA + 600 mg DHA for 3 months significantly reduced symptoms and decreased eye inflammation markers as effectively as anti-inflammatory corticosteroid eye drops, though it took 3 months versus 2 weeks (Downie, Invest Ophthalmol Vis Sci 2018). Fish oil also helped dry eye from computer use in an Indian population with low fish intake (Bhargava, Contact Lens & Ant Eye 2015) [3].

Krill oil (945 mg EPA + 510 mg DHA) for 3 months reduced tear salt content and improved dry eye symptoms compared to placebo, performing similarly to fish oil (Deinema, Ophthalmology 2017) [3].

Retinal Disease

Dietary intake of EPA and DHA from fish is associated with lower eye disease risk, but supplementation has not shown benefit [3].

Women consuming at least one serving of fish per week had a 42% reduced risk of AMD (Christen, Arch Opthamol 2011). However, adding 350 mg DHA + 650 mg EPA to a vitamin combination did not slow AMD progression in the large AREDS2 study (AREDS2 Res Grp, JAMA 2013), and 5 years of fish oil in VITAL did not reduce AMD risk or progression (Christen, JAMA Ophthalmol 2020) [3].

Older people with type 2 diabetes consuming approximately 500 mg EPA+DHA from food weekly were 46% less likely to develop sight-threatening diabetic retinopathy over 6 years (Sala-Vila, JAMA Ophthalmol 2016), but 1 g/day fish oil supplementation for 6.5 years did not decrease diabetic retinopathy risk (Sammons, Ophthalmology 2023) [3].

Liver Disease (MASLD)

Larger, well-controlled studies have shown no benefit of fish oil for reducing liver fat in MASLD [3].

A study of 167 adults with early-stage MASLD found fish oil (1,140 mg DHA + 1,380 mg EPA daily for 5.5 months) did not decrease liver fat compared to olive oil placebo (Tobin, Nutrients 2018). Another study of 51 adults with MASLD found 3.6 g/day fish oil for 1 year did not improve liver fat, fibrosis, or most biomarkers (Smid, Hepatol Commun 2022). DHA alone (1,890 mg/day for 6 months) was also not beneficial (Alkhouri, Aliment Pharmacol Ther 2024) [3].

However, a meta-analysis of 22 trials showed omega-3 supplementation can lower triglycerides among people with MASLD and hypertriglyceridemia (Lee, Nutrients 2020). The AASLD recommends omega-3 fatty acids along with statin therapy for MASLD patients with poorly controlled triglycerides (Rinella, Hepatology 2023) [3].

Migraine Headache

Getting more omega-3 from the diet while reducing omega-6 intake may reduce migraine frequency. Among 141 adults with chronic or episodic migraine, a diet providing 1,500 mg/day EPA+DHA from fish decreased total headache hours by 1.7 hours/day compared to low-omega-3 diets. Reducing linoleic acid intake as well decreased headache days by 2 per month more than omega-3 alone. Both fish oil diets increased blood levels of 17-HDHA, a derivative of DHA with pain-relieving effects (Ramsden, BMJ 2021) [3].

Fish oil supplements have also shown benefit. In 60 migraine patients, 400 mg EPA + 350 mg DHA twice daily for 8 weeks (with low-dose amitriptyline) resulted in 66.7% achieving an 80% reduction in headache days versus 33.3% with placebo (Soares, Nutr Neurosci 2017). However, a larger French study (n=183) found only modest benefit: 55% vs 45% reduction in attacks with fish oil vs placebo over 16 weeks, and no significant difference in the final 4 weeks (Pradalier, Cephalalgia 2001) [3].

EPA alone may help, particularly in women. A study of 70 adults with episodic migraines found 900 mg EPA daily for 12 weeks reduced migraine frequency by 4.4 days/month versus 0.6 days with placebo. The effect was entirely driven by women (-4.9 vs -0.4 days/month); men showed no benefit (Wang, Brain Behav Immun 2024) [3].

Muscle, Strength, and Falls

Older Adults

In 94 older adults (average age 71), 4 g/day krill oil for 6 months increased knee extensor muscle strength by 7.1%, grip strength by 10.9%, and muscle thickness by 3.5% compared to placebo. No improvements were seen in walking speed or chair rise tests (Alkhedhairi, Clin Nutr 2022) [3].

In healthy older adults, high-dose fish oil (2,100 mg EPA + 600 mg DHA) with resistance exercise increased muscle strength by 34% in women -- significantly more than the 16% increase with placebo. Men did not benefit significantly. The researchers speculated that older women may have greater capacity for improvement from resistance exercise (Da Boit, Am J Clin Nutr 2016) [3].

In 63 healthy older adults, ~2,700 mg EPA + 1,200 mg DHA daily for 6 months modestly improved leg extension strength by ~7.5% versus ~3.1% with placebo, but did not improve exercise endurance, muscle mass, or muscle power (Kunz, Nutrients 2022) [3].

A 6-month study found high-dose Lovaza (1,860 mg EPA + 1,500 mg DHA) increased muscle mass by ~3.5% and strength by ~6% in healthy older adults, making up for 2-3 years of losses from normal aging. Changes were similar to or greater than those reported with testosterone, growth hormone, or DHEA, but less than with exercise (Smith, AJCN 2015) [3].

Fish oil supplementation (167 mg EPA + 333 mg DHA from algal oil daily for 3 years) reduced falls by 10% among ~2,000 healthy, active older adults with adequate vitamin D levels, though it did not reduce injurious falls (Bischoff-Ferrari, Am J Clin Nutr 2022) [3].

Younger Adults

In female soccer players, very high-dose fish oil (~4,900 mg EPA + 1,400 mg DHA daily) for 1 month increased running distance by 203 meters more than placebo (63 meters) (Gravina, Int J Sport Nutr Exerc Metab 2017) [3].

In young women with one leg experimentally immobilized, pre-treatment with high-dose fish oil (2,970 mg EPA + 2,030 mg DHA for 4 weeks before immobilization) reduced muscle volume decline (8% vs 14%) and allowed full recovery 2 weeks after brace removal, while the control group did not recover. Muscle synthesis was higher throughout (McGlory, FASEB J 2019) [3].

Fish oil (2,275 mg EPA + 1,575 mg DHA for 10 weeks with resistance exercise) increased bench press by an extra 5 kg compared to placebo but did not improve squats, lean body mass, or body fat in recreationally active young adults (Heileson, J Int Soc Sports Nutr 2023) [3].

Insulin Sensitivity and Blood Sugar

Fish oil may modestly improve insulin sensitivity in non-diabetic populations. In 68 overweight/obese adults, 1 g fish oil (460 mg DHA + 60 mg EPA) twice daily for 3 months reduced fasting insulin by 1.62 uIU/L and improved HOMA-IR by -0.40 units compared to placebo, but did not affect fasting glucose or cholesterol (Abbott, Prostaglandins Leukot Essent Fatty Acids 2020) [3].

In a pilot study of 32 overweight/obese adults with type 2 diabetes, 4 g/day fish oil for 8 weeks improved insulin sensitivity, reduced triglycerides, and increased HDL, though there was no control group (de Souza, J Diab Complications 2020) [3].

Consuming fatty fish (salmon) 5 times per week for 8 weeks significantly improved post-meal blood sugar regulation, while lean fish (cod) did not (Helland, Br J Nutr 2017) [3].

However, a 14-month study in 359 adults with type 2 diabetes showed that 1.5 or 3 g/day omega-3 did not reduce carotid plaques or new plaque incidence compared to olive oil placebo, though high-dose supplementation did reduce triglycerides (Zhuang, Cardiovasc Diabetol 2026) [3].

Testosterone and Fertility

In overweight/obese men, 1 g fish oil (430 mg DHA + 60 mg EPA) twice daily for 3 months significantly increased total testosterone by more than 10% compared to placebo, but not in women (Kylie, Prostaglandins Leukot Essent Fatty Acids 2020) [3].

A study of 1,679 healthy young men in Denmark found fish oil supplement use over the prior 3 months was associated with significantly better semen volume, sperm count, and testicular size, particularly with 60+ days of use. No such association was found with multivitamins or vitamins C or D (Jensen, JAMA Net Open 2020) [3].

However, high doses (5 g EPA+DHA daily for 1 month) did not increase free or total testosterone (Hughes, Atherosclerosis 1990), and 400 mg/day EPA+DHA did not affect testosterone in older men with heart attack history (Giltay, Int J Androl 2012) [3].

Epilepsy

A well-controlled study found low-dose fish oil (1,080 mg EPA+DHA per day) for 10 weeks reduced seizure frequency by 33.6% compared to placebo in people with drug-resistant epilepsy. Interestingly, double the dose was not effective. The researchers proposed that high-dose fish oil may cause excessive reductions in non-esterified fatty acids, and noted a similar pattern in depression research (DeGiorgio, J Neurol Neurosurg Psychiatry 2014) [3].

ADHD and Cognitive Function in Children

Results are conflicting. High-dose EPA (1,200 mg daily) improved focused attention in children with ADHD, particularly those with low baseline EPA levels, but worsened impulsivity compared to placebo. An expert panel recommended 750+ mg/day EPA+DHA for at least 12 weeks for patients who prefer omega-3 over stimulants, but not if already getting adequate omega-3 from diet (Chang, Translational Psych 2019; Banaschewski, Nutr Health 2018) [3].

A study of children with mood disorders found 700 mg EPA + 100 mg DHA daily for 3 months improved parent-reported executive functioning compared to placebo (Vesco, J Child Psychol Psychiatry 2017). However, algal DHA alone (300 mg/day for 6 months) did not improve executive function in healthy children (Yang, Eur J Nutr 2020) [3].

Consumption of oily fish (~11 oz/week for 3 months, increasing EPA+DHA from ~135 to 913 mg/day) modestly improved attention and cognitive flexibility in 8-9-year-old Danish children compared to poultry (Teisen, Am J Clin Nutr 2020) [3].

A study of boys aged 8-14 found fish oil (650 mg EPA + 650 mg DHA daily in margarine for 16 weeks) modestly improved parent-rated attention in boys with ADHD and in typically developing boys, but had no effect on brain activity or cognitive task performance (Bos, Neuropsychopharm 2015). In Swedish children ages 9-10, 558 mg EPA + 174 mg DHA + 60 mg GLA daily for 3 months improved reading ability, with greatest improvements in children with attention problems (Johnson, J Child Psychol Psychiatry 2016) [3].

Psychosis and Schizophrenia

Despite initially promising results (Amminger, Arch Gen Psychiatry 2010 showed only 4.9% vs 27.5% developed psychosis with fish oil vs placebo over 1 year), subsequent larger studies have not confirmed fish oil prevents psychosis in at-risk individuals (McGorry, JAMA Psychiatry 2016; Winter-van Rossum, Schizophr Bull 2024) [3].

For first-episode schizophrenia, 1,320 mg EPA + 880 mg DHA daily for 26 weeks resulted in 69.4% experiencing at least 50% symptom improvement versus 40% with placebo, with the greatest improvements in depressive symptoms (Pawelczyk, J Psych Res 2016) [3].

Other Conditions

Acne: 1,000 mg EPA + 1,000 mg DHA daily for 10 weeks reduced inflammatory acne lesions by 42.6% and non-inflammatory lesions by 19.6% in young adults with mild to moderate acne (Jung, Acta Derm Venereol 2014) [3].

Periodontitis: 2,000 mg/day DHA with low-dose aspirin (81 mg) improved pocketing and inflammation in periodontitis patients over 3 months (Naqvi, J Dent Res 2014). However, high-dose EPA+DHA (900 mg DHA + 1,300 mg EPA twice daily) for 6 months did not improve pocketing after dental deep cleaning (Stando-Retecka, BMC Oral Health 2023) [3].

Air pollution protection: Fish oil (1,230 mg EPA + 822 mg DHA daily for 4 weeks) protected against adverse cardiac and lipid effects of air pollution exposure, while olive oil did not. However, olive oil was better at protecting endothelial function from air pollution (Tong, Env Health Perp 2012; Tong, AJRCCM 2014) [3].

Menopause symptoms: Fish oil (180 mg EPA + 120 mg DHA daily) for 3 months reduced sweating, hot flashes, sleep problems, and mood symptoms compared to placebo, with efficacy similar to soybean extract (Purzand, Complement Ther Clin Pract 2020) [3].

Burning mouth syndrome: 2 g omega-3 (1,200 mg EPA + 800 mg DHA) daily for 12 weeks reduced burning pain severity by 4.4 points (on 10-point scale) versus 1.2 points with placebo (Srivastava, J Pharm Bioallied Sci 2025) [3].

COVID-19: High-dose Vascepa did not significantly reduce COVID hospitalizations or death (Dharam, J Am Coll Cardiol 2021). Fish oil did not improve long COVID symptoms (Sarkar, Cureus 2024) [3].

Asthma in existing patients: High-dose fish oil (3,180 mg EPA + 822 mg DHA) for 24 weeks did not improve lung function or reduce exacerbations in overweight/obese young people with poorly controlled asthma (Lang, Ann Am Thorac Soc 2019) [3].

Suicide risk: Military personnel who committed suicide had significantly lower blood DHA levels than those who did not. Risk of suicide was 62% greater among men with serum DHA below 1.75% (Lewis, J Clin Psychiatry 2011) [3].

4. Recommended Dosing

General Population

The American Heart Association recommends at least 1-2 servings (3.5 oz each) of non-fried, preferably fatty fish per week, providing approximately 250-500 mg/day of EPA+DHA [7]. For people who do not eat fish regularly, a supplement providing 500-1,000 mg of combined EPA+DHA daily is a reasonable approach.

Adequate Intakes (AIs) for Total Omega-3s

From the IOM [1][2]:

Age Group	Male (g/day)	Female (g/day)
1-3 years	0.7	0.7
4-8 years	0.9	0.9
9-13 years	1.2	1.0
14-18 years	1.6	1.1
19+ years	1.6	1.1
Pregnancy	--	1.4
Lactation	--	1.3

Note: These AIs are for ALA only (ages 1+). No specific DRIs for EPA or DHA have been established.

Dosing by Indication

General cardiovascular support: 500-1,000 mg EPA+DHA per day from fish and/or supplements. This is the most commonly studied dose in the general population [3][7][10].

Triglyceride reduction: 2,000-4,000 mg EPA+DHA per day, under physician supervision. The AHA recommends prescription omega-3s at 4 g/day as effective and safe for reducing triglycerides (Skulas-Ray, Circulation 2019) [7].

After heart attack or established coronary heart disease: ~1 g/day EPA+DHA (AHA recommendation), preferably from fatty fish; supplements under physician direction [7].

Depression (adjunctive therapy): 1,000-4,000 mg/day with EPA:DHA ratio >2:1. The International Society for Nutritional Psychiatry Research recommends 1-2 g/day for at least 8 weeks (Guu, Psychother Psychosom 2019) [3].

Rheumatoid arthritis pain: 2,000-3,500 mg/day EPA+DHA, with products having at least 50% more EPA than DHA [3].

Pregnancy (preterm birth prevention): At least 250 mg/day DHA+EPA plus an additional 100-200 mg/day DHA. Women at risk of preterm birth: 600-1,000 mg/day DHA+EPA, starting by 20 weeks gestation through 37 weeks. Consider discontinuation in the third trimester due to postpartum hemorrhage risk (Cetin, Am J Obstet Gynecol MFM 2024) [3].

Cognitive function in older adults: 900-2,000 mg/day DHA, particularly in people with low baseline levels and low fish intake [3].

Migraine prevention: 1,500 mg/day EPA+DHA from dietary fish, ideally with reduced omega-6 intake. From supplements: 750-1,800 mg/day EPA [3].

Epilepsy: ~1,080 mg EPA+DHA per day. Higher doses may not be effective [3].

How to Take

• Take with a fatty meal to maximize absorption. Fats trigger bile release, emulsifying the oil for better uptake (Dyerberg, PLEFA 2010) [9].
• Divide doses (e.g., twice daily) for better tolerance and absorption of larger doses [9].
• Keep fish oil fresh. Store out of heat and light, refrigerate after opening, and freeze if not using soon. Slight cloudiness after refrigeration is normal. If using bottled liquid, purchase a size to be used within a few weeks [9].
• Products containing added antioxidants (vitamin E, rosemary, ascorbic acid) help maintain freshness [9].
• Enteric-coated pills may reduce fishy burps by releasing oils in the intestine rather than the stomach. If you notice oily stools, the coating may not be dissolving properly [9].

Omega-3 Index Testing

The omega-3 index (EPA+DHA as percentage of red blood cell fatty acids) is the most established biomarker, reflecting intake over approximately 120 days. An index of ~8% is associated with lower cardiovascular risk; below 4% is the highest risk (Harris, Atherosclerosis 2017). OmegaQuant offers direct-to-consumer testing (~$55/test), while Quest Diagnostics and Boston Heart Diagnostics offer provider-ordered testing. However, analytical methods are not standardized and results can vary between laboratories (von Schacky, Nutrients 2014). The test does not distinguish between EPA and DHA, which may have different biological effects (Dicklin, J Nutr 2024) [4][5].

5. Safety and Side Effects

Common Side Effects

The most common side effects of fish oil supplementation are [3][9]:

• Fishy-smelling burps
• Diarrhea
• Gastrointestinal upset, indigestion, heartburn, or reflux
• Nausea, gas, and bloating

These can be minimized by taking fish oil in smaller, divided doses just before meals, lying on the left side after eating, or using enteric-coated capsules [3].

Upper Limit

Unless medically prescribed, it is generally recommended not to exceed 3 g/day of combined EPA+DHA, with no more than 2 g/day from dietary supplements. The FDA states that dietary supplements should not recommend more than 2 g/day EPA+DHA [1][10].

Higher doses may suppress the immune system. A review found very high amounts of EPA and DHA dampened immunity in animals, resulting in reduced survival from bacterial, viral, and fungal infections. In human terms, this would correspond to approximately 2,200-22,000 mg/day (Fenton, Prostag Leukotri EFAs 2013). This is a concern primarily for immunocompromised individuals taking high-dose supplements [3].

Atrial Fibrillation

High-dose fish oil supplements may increase the risk of atrial fibrillation, particularly in people with heart problems [3]:

• Among healthy people in the UK, regular fish oil supplementation was associated with a 13% higher risk of developing atrial fibrillation and a 5% higher risk of stroke compared to non-use over ~12 years, though it was associated with an 8% reduced risk of heart failure (Chen, BMJ Med 2024) [3]
• In people with pre-existing heart disease, 1-4 g/day omega-3 for 1+ years may increase the overall relative risk of atrial fibrillation by 25% (Gencer, Circulation 2021) [3]
• Vascepa: atrial fibrillation in 3.1% vs 2.1% with placebo (Bhatt, NEJM 2018) [3]
• Epanova: atrial fibrillation in 2.2% vs 1.3% with placebo (Nicholls, JAMA 2020) [3]
• Even lower-dose concentrated fish oil (1.8 g providing 930 mg EPA + 660 mg DHA) showed a trend toward increased atrial fibrillation (7.2% vs 4% on placebo) in a 2-year study of older people with recent heart attacks (Kalstad, Circulation 2020) [3]
• A large Japanese study found 1,800 mg/day icosapent ethyl doubled the rate of new-onset atrial fibrillation (3.1% vs 1.6%) (Miyauchi, Circulation 2024) [3]
• Even 1 g/day concentrated fish oil (Omacor) for 2 years caused statistically significant changes in cardiac electrical signals, including slowed atrial conduction (Tikkanen, Sci Rep 2023) [3]
• A review of five large trials concluded omega-3 supplementation increases atrial fibrillation risk in people with elevated triglycerides and/or cardiovascular risk (Lombardi, Eur Heart J Cardiovasc Pharmacother 2021) [3]

Bleeding Risk

Fish oil may have a blood-thinning effect, especially at doses above 3 g/day EPA+DHA (Zucker, Atherosclerosis 1998). Doses below 1 g omega-3/day do not appear to have this effect (Bays, Am J Cardio 2007) [3].

High-dose Vascepa was associated with a tripling in the risk of bleeding events among people also taking antithrombotic drugs (aspirin, clopidogrel, warfarin, heparin, apixaban) but did not increase bleeding in those not on such medications (Cai, Expert Opin Drug Saf 2023) [3].

Among people on warfarin, clotting time (INR) has been shown to increase upon beginning or increasing fish oil supplementation, returning to normal after discontinuation. There is at least one case report of fatal uncontrollable brain bleeding in an elderly man on warfarin and fish oil after head trauma (Gross, J Trauma Nursing 2017) [3].

However, a large study of 1,500+ cardiac surgery patients found taking 8-10 g of Lovaza before surgery did not increase surgical bleeding, and those with higher omega-3 blood levels actually had lower bleeding risk (Akintoye, Circ Cardiovasc Qual Outcomes 2018) [3].

High-dose fish oil supplementation may also increase the risk of eye bleeding. A 32-year-old man with extreme nearsightedness experienced two macular hemorrhages while taking 1,000 mg fish oil (400 mg DHA + 600 mg EPA) daily. After discontinuation, the hemorrhage healed within 8 weeks (Li, SAGE Open Med Case Rep 2020) [3].

Pregnancy Concerns

Use of omega-3 supplements during pregnancy was associated with a 25% increased risk of postpartum hemorrhage and a 470% increased risk of massive postpartum hemorrhage after cesarean delivery (but not vaginal delivery), in a large Swedish study. Researchers advise considering discontinuation in the third trimester (Lichtenstein, Acta Obstet Gynecol Scand 2024) [3].

LDL Cholesterol

High-dose fish oil supplementation may increase LDL cholesterol in some individuals. This is noted as a possible serious side effect of prescription Lovaza and Epanova [3]. DHA may be more likely to raise LDL than EPA. Algal DHA caused an 8% increase in LDL, although the LDL particles became larger (potentially less atherogenic) (Bernstein, J Nutr 2012). DHA is also more effective than EPA at increasing HDL2 cholesterol, the subfraction most protective against coronary heart disease (Mori, Am J Clin Nutr 2000) [3].

Krill Oil and Insulin Sensitivity

A study of overweight men given 5 g/day of krill/fish oil blend for 8 weeks showed reduced insulin sensitivity by approximately 27%, potentially increasing diabetes and cardiovascular risk. The researchers speculate krill proteins attached to phospholipids may be responsible (Albert, Am J Clin Nutr 2015) [3].

Fish Allergy

Some people are allergic to proteins in fish, krill, and calamari. A small study of six fish-allergic patients found no reaction to fish oil supplements (Mark, Allergy Asthma Proc 2008), though there is at least one case report of a reaction to an omega-3 fish oil capsule (Kmet, Can Fam Phys 2012). If allergic to fish, krill, or calamari, use caution with refined oils [3].

Contaminants

Mercury is not a known contaminant in fish oil supplements -- it has never been detected by testing. Mercury is primarily a concern in fish meat, not refined oils [3][9]. Microplastics larger than 0.5-1 micrometer are not present in refined fish oils (GOED 2018) [9]. PCB levels in fish oil supplements are extremely low -- a typical serving contains far less than a 3-ounce serving of salmon [9]. PFAS compounds from fish oil supplements do not increase blood PFAS levels (Onteeru, Environ Res 2022) [9].

Despite long-term fish oil not seeming to adversely affect the liver, fish liver oils (such as cod liver oil) can contain high levels of vitamin A, which can cause liver toxicity if combined with other vitamin A sources [3].

Hair Loss

A study in mice fed extremely high fish oil (45% of total calories) showed hair loss, but this is not relevant to standard supplementation. The association may relate to vitamin A (retinol) naturally found in fish oil from liver sources (Hao, Cell Report 2023; Hagino, Clin Cos Investig Derm 2021) [3].

6. Drug Interactions

Drug	Interaction	Management
Warfarin, heparin, apixaban, clopidogrel, aspirin	Fish oil may enhance anticoagulant effect, increasing bleeding risk. High-dose Vascepa tripled bleeding risk in those on antithrombotics (Cai, Expert Opin Drug Saf 2023)	Monitor INR; use caution with >1 g/day EPA+DHA. Lower doses (<1 g) do not appear to affect bleeding [3]
Blood pressure medications	Fish oil may further lower blood pressure	Monitor blood pressure [3]
Statins (atorvastatin, rosuvastatin, simvastatin, pitavastatin)	Statins may lower omega-3 blood levels. Fenofibrate decreased ALA and DHA levels (de Lorgeril, Nutr Metab Cardiovasc Dis 2005). Combining fish oil with statins is generally safe and may beneficially lower triglycerides	Combination is often beneficial for lipids; does not argue against concurrent use [3]
Tacrolimus (Astagraf, Envarsus, Protopic)	High-dose omega-3 (2,600 mg/day) increased tacrolimus blood concentrations by 25% via CYP3A inhibition. May not be reflected in trough concentrations (Robertsen, Transpl Int 2021)	Monitor tacrolimus levels when initiating or stopping fish oil [3]
Cyclosporine (Neoral, Sandimmune), sirolimus (Rapamune)	High-dose omega-3 may raise levels of these immunosuppressants via CYP3A interaction (Cortinovis, Transplantation 2010; Busnach, J Nephrol 1998)	Monitor drug levels [3]
Chemotherapy agents	16:4(n-3) fatty acid in fish oil may activate chemoresistance (Daenen, JAMA Oncology 2015)	Avoid fish oil from the day before through the day after chemotherapy; avoid herring and mackerel for 48 hours around treatment [3]
SSRIs (fluoxetine, sertraline) and other antidepressants	Additive antidepressant effect. EPA-rich omega-3 may enhance SSRI efficacy (Sarris, Am J Psychiatry 2016)	Combination may be beneficial; monitor response [3]

7. Dietary Sources

Top Dietary Sources of EPA and DHA

Food	Serving	DHA (mg)	EPA (mg)	Total EPA+DHA (mg)
Salmon, Atlantic, farmed, cooked	3 oz	1,240	590	1,830
Herring, Atlantic, cooked	3 oz	940	770	1,710
Salmon, Atlantic, wild, cooked	3 oz	1,220	350	1,570
Sardines, canned in tomato sauce	3 oz	740	450	1,190
Mackerel, Atlantic, cooked	3 oz	590	430	1,020
Salmon, pink, canned	3 oz	630	280	910
Trout, rainbow, wild, cooked	3 oz	440	400	840
Sea bass, cooked	3 oz	470	180	650
Oysters, eastern, wild, cooked	3 oz	230	300	530
Shrimp, cooked	3 oz	120	120	240
Tuna, light, canned in water	3 oz	170	20	190
Lobster, cooked	3 oz	70	100	170
Cod, Pacific, cooked	3 oz	100	40	140

Source: USDA FoodData Central [1][11].

Top Sources of ALA

Food	Serving	ALA (mg)
Flaxseed oil	1 tbsp	7,260
Chia seeds	1 oz	5,060
English walnuts	1 oz	2,570
Flaxseed, whole	1 tbsp	2,350
Canola oil	1 tbsp	1,280
Soybean oil	1 tbsp	920
Edamame, frozen	1/2 cup	280

Source: USDA FoodData Central [1][11].

Practical Notes on Dietary Omega-3s

• Farmed salmon generally has higher EPA+DHA content than wild-caught, but levels have decreased significantly (2006-2015) as traditional marine feed ingredients are replaced [1][9]
• Grass-fed beef contains somewhat more omega-3s (mainly ALA) than grain-fed beef, but amounts are very low [1]
• DHA-fortified eggs typically provide about 150 mg DHA per egg. Fortified foods generally provide 50-100 mg EPA/DHA per serving -- insufficient as a sole source [9]
• Mercury concern: Levels are highest in shark, swordfish, king mackerel, and tilefish (~1,000 ppb). Most other fish contain one-tenth to one-third as much. Mercury is not a concern in fish oil supplements [1][9]
• Salmon skin: The fatty layer underneath the skin is richest in omega-3s. DHA and EPA are also distributed throughout the flesh, especially in the red muscle and belly areas (Aursand, J Sci Agr 2006) [9]
• AHA recommendation: At least 2 servings (3.5 oz each) of non-fried, preferably fatty fish per week. For people with heart disease, some experts recommend 4 servings of fatty fish per week [7][9]

8. References

[1] National Institutes of Health, Office of Dietary Supplements. "Omega-3 Fatty Acids -- Health Professional Fact Sheet." Updated 2024. https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/

[2] Institute of Medicine. "Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids." National Academies Press, 2005.

[3] ConsumerLab. "Fish Oil and Omega-3 Fatty Acid Supplements Review." Accessed 2026. https://www.consumerlab.com/reviews/fish-oil-supplements-review/omega3/

[4] Harris WS, Von Schacky C. "The Omega-3 Index: a new risk factor for death from coronary heart disease?" *Prev Med*. 2004;39(1):212-220. doi: 10.1016/j.ypmed.2004.02.030

[5] Harris WS, et al. "The Omega-3 Index and relative risk for coronary heart disease mortality." *Atherosclerosis*. 2017;262:21-27. doi: 10.1016/j.atherosclerosis.2017.04.015

[6] Murphy RA, et al. "Long-chain omega-3 fatty acid status in the general population." *BMJ Open*. 2021. doi: 10.1136/bmjopen-2020-044320

[7] Rimm EB, Appel LJ, Chiuve SE, et al. "Seafood Long-Chain n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease: A Science Advisory From the American Heart Association." *Circulation*. 2018;138(1):e35-e47. doi: 10.1161/CIR.0000000000000574

[8] Skulas-Ray AC, Wilson PWF, Harris WS, et al. "Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association." *Circulation*. 2019;140(12):e673-e691. doi: 10.1161/CIR.0000000000000709

[9] ConsumerLab. "Fish Oil and Omega-3 Fatty Acid Supplements -- ConsumerTips (forms, absorption, dosing)." Accessed 2026. https://www.consumerlab.com/reviews/fish-oil-supplements-review/omega3/

[10] Hu Y, Hu FB, Manson JE. "Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127,477 Participants." *J Am Heart Assoc*. 2019;8(19):e013543. doi: 10.1161/JAHA.119.013543

[11] U.S. Department of Agriculture, FoodData Central. https://fdc.nal.usda.gov/

[12] Manson JE, Cook NR, Lee IM, et al. "Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer." *N Engl J Med*. 2019;380(1):23-32. doi: 10.1056/NEJMoa1811403

[13] Bhatt DL, Steg PG, Miller M, et al. "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia." *N Engl J Med*. 2019;380(1):11-22. doi: 10.1056/NEJMoa1812792

[14] ASCEND Study Collaborative Group. "Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus." *N Engl J Med*. 2018;379(16):1540-1550. doi: 10.1056/NEJMoa1804989

[15] Nicholls SJ, Lincoff AM, Garcia M, et al. "Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial." *JAMA*. 2020;324(22):2268-2280. doi: 10.1001/jama.2020.22258

[16] Li ZH, Zhong WF, Liu S, et al. "Associations of habitual fish oil supplementation with cardiovascular outcomes and all cause mortality: evidence from a large population based cohort study." *BMJ*. 2020;368:m456. doi: 10.1136/bmj.m456

[17] Lok CE, Bhatt DL, Engelen DJPE, et al. "Effect of Fish Oil on Major Cardiovascular Events in Adults on Hemodialysis." *N Engl J Med*. 2025. doi: 10.1056/NEJMoa2411254

[18] Firth J, Teasdale SB, Allott K, et al. "The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized controlled trials." *World Psychiatry*. 2019;18(3):308-324. doi: 10.1002/wps.20672

[19] Guu TW, Mischoulon D, Sarris J, et al. "International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder." *Psychother Psychosom*. 2019;88(5):263-273. doi: 10.1159/000502652

[20] Ramsden CE, Zamora D, Majchrzak-Hong S, et al. "Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine." *BMJ*. 2021;374:n1448. doi: 10.1136/bmj.n1448

[21] Quinn JF, Raman R, Thomas RG, et al. "Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial." *JAMA*. 2010;304(17):1903-1911. doi: 10.1001/jama.2010.1510

[22] Bisgaard H, Stokholm J, Chawes BL, et al. "Fish Oil-Derived Fatty Acids in Pregnancy and Wheeze and Asthma in Offspring." *N Engl J Med*. 2016;375(26):2530-2539. doi: 10.1056/NEJMoa1503734

[23] Asbell PA, Maguire MG, Pistilli M, et al. "n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease." *N Engl J Med*. 2018;378(18):1681-1690. doi: 10.1056/NEJMoa1709691

[24] Bischoff-Ferrari HA, Vellas B, Rizzoli R, et al. "Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults." *Front Nutr*. 2022. doi: 10.3389/fnut.2022.894273

[25] Song M, Nishihara R, Wu K, et al. "Marine omega-3 polyunsaturated fatty acids and risk for colorectal cancer." *JAMA Oncol*. 2019. doi: 10.1001/jamaoncol.2019.3728

[26] Di Giuseppe D, Wallin A, Bottai M, et al. "Long-chain omega-3 fatty acids and risk of rheumatoid arthritis." *Ann Rheum Dis*. 2013;73(11):1949-1953. doi: 10.1136/annrheumdis-2013-203338

[27] Hahn J, Cook NR, Alexander EK, et al. "Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial." *BMJ*. 2022;376:e066452. doi: 10.1136/bmj-2021-066452

[28] Makrides M, Gibson RA, McPhee AJ, et al. "Effect of DHA Supplementation During Pregnancy on Maternal Depression and Neurodevelopment of Young Children." *JAMA*. 2010;304(15):1675-1683. doi: 10.1001/jama.2010.1507

[29] Carlson SE, Gajewski BJ, Valentine CJ, et al. "Higher dose docosahexaenoic acid supplementation during pregnancy and early preterm birth." *EClinicalMedicine*. 2021;36:100905. doi: 10.1016/j.eclinm.2021.100905

[30] Gencer B, Djousse L, Al-Ramady OT, et al. "Effect of Long-Term Marine omega-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation." *Circulation*. 2021;144(25):1981-1990. doi: 10.1161/CIRCULATIONAHA.121.055654

[31] Abdelhamid AS, Brown TJ, Brainard JS, et al. "Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease." *Cochrane Database Syst Rev*. 2018;11(11):CD003177. doi: 10.1002/14651858.CD003177.pub4

[32] DeGiorgio CM, Miller PR, Harper R, et al. "Fish oil (n-3 fatty acids) in drug resistant epilepsy: a randomised placebo-controlled crossover study." *J Neurol Neurosurg Psychiatry*. 2015;86(1):65-70. doi: 10.1136/jnnp-2014-307749

[33] Jensen TK, Priskorn L, Holmboe SA, et al. "Associations of Fish Oil Supplement Use With Testicular Function in Young Men." *JAMA Netw Open*. 2020;3(1):e1919462. doi: 10.1001/jamanetworkopen.2019.19462

[34] Daenen LG, Cirkel GA, Houthuijzen JM, et al. "Increased Plasma Levels of Chemoresistance-Inducing Fatty Acid 16:4(n-3) After Consumption of Fish and Fish Oil." *JAMA Oncol*. 2015;1(3):350-358. doi: 10.1001/jamaoncol.2015.0829

[35] Smith GI, Julliand S, Reeds DN, et al. "Fish oil-derived n-3 PUFA therapy increases muscle mass and function in healthy older adults." *Am J Clin Nutr*. 2015;102(1):115-122. doi: 10.3945/ajcn.114.105833

[36] Dyerberg J, Madsen P, Moller JM, et al. "Bioavailability of marine n-3 fatty acid formulations." *Prostaglandins Leukot Essent Fatty Acids*. 2010;83(3):137-141. doi: 10.1016/j.plefa.2010.06.007

[37] Middleton P, Gomersall JC, Gould JF, et al. "Omega-3 fatty acid addition during pregnancy." *Cochrane Database Syst Rev*. 2018;11(11):CD003402. doi: 10.1002/14651858.CD003402.pub3